-
Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
Gerald Illerhaus, Andrés J.M. Ferreri, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer, +43 more
44citations -
The Clinical Picture of the ERCC6L2 Disease - from Bone Marrow Failure to Acute Leukemia2023 Blood article Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Marja Hakkarainen, Ilse Kaaja, Suvi P. M. Douglas, Thomas J. Vulliamy, Inderjeet S Dokal, Jean Pierre Soulier, +23 more
42citations -
Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis2023 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, James K. McCloskey, Francesca Palandri, Steffen Koschmieder, +18 more
42citations -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Régis Peffault de Latour, Alexander Roeth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M. de Castro, +15 more
23citations -
Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial
Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela Maria Baerlocher, Jiřı́ Mayer, Tim H. Brümmendorf, +21 more
21citations -
Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial
Tsewang Tashi, Olivier Hermine, Mariana Castells, Mar Guilarte, Vito Sabato, Marcus Maurer, +26 more
19citations -
Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
Christian Straka, Kerstin Schaefer‐Eckart, Bernd Hertenstein, Florian C. Bassermann, Hans Jürgen Salwender, Christian H. Langer, +32 more
17citations